Townsquare Capital LLC Has $11.32 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Townsquare Capital LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.4% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 134,964 shares of the biopharmaceutical company’s stock after buying an additional 16,996 shares during the quarter. Townsquare Capital LLC’s holdings in Gilead Sciences were worth $11,315,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. CarsonAllaria Wealth Management Ltd. raised its stake in Gilead Sciences by 198.3% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 238 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at approximately $25,000. Valued Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the period. Cedar Wealth Management LLC grew its position in Gilead Sciences by 51.6% during the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 160 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences during the 2nd quarter worth $33,000. Institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 63,735 shares of company stock worth $5,589,030. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

GILD stock opened at $92.41 on Thursday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90. The company has a market capitalization of $115.17 billion, a P/E ratio of 1,026.78, a PEG ratio of 2.81 and a beta of 0.17. The company has a fifty day moving average price of $87.91 and a 200-day moving average price of $77.42.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.29 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 4.37 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.33%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on GILD shares. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Sanford C. Bernstein began coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 price objective on the stock. Citigroup initiated coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price for the company. Royal Bank of Canada increased their price target on shares of Gilead Sciences from $81.00 to $84.00 and gave the stock a “sector perform” rating in a research report on Monday, November 18th. Finally, Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $74.00 to $96.00 in a research report on Monday, October 21st. Twelve investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $95.41.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.